Recombinant GDF15 prophylaxis attenuates cardiorenal toxicity and fibrosis induced by doxorubicin and angiotensin II
10 affiliations
- 1School of Medicine, The Hong Kong University of Science and Technology, 5th floor, Academic Building, Clear Water Bay, Kowloon, Hong Kong SAR, China
- 2Laboratory for Heart Failure + Circulation Research, Li Ka Shing Institute of Health Sciences, and Gerald Choa Cardiac Research Centre, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China
- 3Centre for Cardiovascular Genomics and Medicine and Hong Kong Hub of Paediatric Excellence, The Chinese University of Hong Kong, Hong Kong Children’s Hospital, Hong Kong SAR, China
- 4School of Public Health, Faculty of Medicine, Imperial College London, London, UK
- 5Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT USA
- 6School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Lo Kwee-Seong Integrated Biomedical Sciences Building, Area 39, Shatin, New Territories, Hong Kong SAR, China
- 7Stanford Cardiovascular Institute, Stanford University, Stanford, CA USA
- 8Inflammatory Disease Laboratory, Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China
- 9Hong Kong Hub of Paediatric Excellence (HK HOPE), The Chinese University of Hong Kong, Hong Kong SAR, China
- 10Ministry of Education Key Laboratory for Regenerative Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China
Abstract
Background: Anthracycline chemotherapy induces cardiotoxicity through mitochondrial damage and cell apoptosis that are exacerbated in vivo by angiotensin II (Ang II). Growth differentiation factor 15 (GDF15) is a stress-responsive cytokine with protective functions but its capacity to mitigate doxorubicin (Dox)-induced cardiotoxicity and Ang II-associated cardiorenal stress remains unclear.
Methods: Human embryonic stem cell-derived cardiomyocytes were used to evaluate Dox toxicity and to benchmark recombinant GDF15 against conventional dexrazoxane pretreatment. Cardiomyocyte viability, mitochondrial integrity and function, apoptosis, and transcriptome profiles by RNA sequencing were evaluated. To determine in vivo efficacy, C57BL/6 J mice were administered GDF15 (0.5 mg/kg, intraperitoneal) 24 h before once weekly Dox (5 mg/kg). Ang II was infused subcutaneously via surgically implanted osmotic pump. Mice were sacrificed for histopathologic analysis 1 week after the fourth cycle of Dox.
Results: In vitro, Dox-induced mitochondrial fragmentation, loss of membrane potential, transcriptional dysregulation, and apoptosis were significantly attenuated by recombinant GDF15 pretreatment, with efficacy comparable to dexrazoxane. Cytotoxic effects of daunorubicin on cardiomyocytes were also attenuated by GDF15. In vivo, Ang II, Dox, and Dox + Ang II induced cardiorenal injury characterized by hypertension, sarcomere disarray, myocardial and renal fibrosis, and glomerular, tubular, and perivascular abnormalities. GDF15 prophylaxis mitigated these pathologic changes, preserved myocardial and renal tissue architecture, and reduced cardiorenal fibrosis.
Conclusions: Recombinant GDF15 pretreatment can protect the heart and kidneys from Dox-induced cardiorenal toxicity and Ang II-exacerbated injury. These findings encourage further investigation into GDF15 as a potential prophylaxis against cardiorenal toxicity associated with anthracycline chemotherapy and renin-angiotensin system activation.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s13578-026-01633-9.
Related
- Renin-Angiotensin System Activation Drives Early Cardiorenal Dysfunction in Normotensive Prediabetes.
- Oral administration of Angiotensin-(1-7) included in hydroxypropyl β-cyclodextrin attenuates cardiac hypertrophy and inflammation in a mouse model of Takotsubo cardiomyopathy
- 1-Methylhistidine attenuates early myocardial inflammation in type 3 cardiorenal syndrome through modulation of the p105/p50 NF-κB axis
- Nanocurcumin Attenuates Doxorubicin‐Induced Cardiotoxicity by Activating the Wnt/β‐Catenin/GSK‐3β Signaling Axis in Wistar Rats
- Phenolic-Rich Aronia melanocarpa (cv. Nero) Extract Attenuates Doxorubicin-Induced Nephrotoxicity Associated with Reduced Oxidative Stress, Inflammation, and Endoplasmic Reticulum Stress
BibTeX
@article{fung2026recombinant,
title = {{Recombinant GDF15 prophylaxis attenuates cardiorenal toxicity and fibrosis induced by doxorubicin and angiotensin II}},
author = {Erik Fung and Hangqi Luo and Jack C. H. Chen and Wenjuan Zhu and Lihua Huang and Yidan Hao and Xiao-Ru Huang and Hui-Yao Lan and Ellen N. Poon},
journal = {Cell \& Bioscience},
year = {2026},
month = aug,
doi = {10.1186/s13578-026-01633-9},
url = {https://doi.org/10.1186/s13578-026-01633-9},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Recombinant GDF15 prophylaxis attenuates cardiorenal toxicity and fibrosis induced by doxorubicin and angiotensin II
AU - Erik Fung
AU - Hangqi Luo
AU - Jack C. H. Chen
AU - Wenjuan Zhu
AU - Lihua Huang
AU - Yidan Hao
AU - Xiao-Ru Huang
AU - Hui-Yao Lan
AU - Ellen N. Poon
PY - 2026
DA - 2026/08/16
JO - Cell & Bioscience
DO - 10.1186/s13578-026-01633-9
UR - https://doi.org/10.1186/s13578-026-01633-9
AB - Background: Anthracycline chemotherapy induces cardiotoxicity through mitochondrial damage and cell apoptosis that are exacerbated in vivo by angiotensin II (Ang II). Growth differentiation factor 15 (GDF15) is a stress-responsive cytokine with protective functions but its capacity to mitigate doxorubicin (Dox)-induced cardiotoxicity and Ang II-associated cardiorenal stress remains unclear. Methods: Human embryonic stem cell-derived cardiomyocytes were used to evaluate Dox toxicity and to benchmark recombinant GDF15 against conventional dexrazoxane pretreatment. Cardiomyocyte viability, mitochondrial integrity and function, apoptosis, and transcriptome profiles by RNA sequencing were evaluated. To determine in vivo efficacy, C57BL/6 J mice were administered GDF15 (0.5 mg/kg, intraperitoneal) 24 h before once weekly Dox (5 mg/kg). Ang II was infused subcutaneously via surgically implanted osmotic pump. Mice were sacrificed for histopathologic analysis 1 week after the fourth cycle of Dox. Results: In vitro, Dox-induced mitochondrial fragmentation, loss of membrane potential, transcriptional dysregulation, and apoptosis were significantly attenuated by recombinant GDF15 pretreatment, with efficacy comparable to dexrazoxane. Cytotoxic effects of daunorubicin on cardiomyocytes were also attenuated by GDF15. In vivo, Ang II, Dox, and Dox + Ang II induced cardiorenal injury characterized by hypertension, sarcomere disarray, myocardial and renal fibrosis, and glomerular, tubular, and perivascular abnormalities. GDF15 prophylaxis mitigated these pathologic changes, preserved myocardial and renal tissue architecture, and reduced cardiorenal fibrosis. Conclusions: Recombinant GDF15 pretreatment can protect the heart and kidneys from Dox-induced cardiorenal toxicity and Ang II-exacerbated injury. These findings encourage further investigation into GDF15 as a potential prophylaxis against cardiorenal toxicity associated with anthracycline chemotherapy and renin-angiotensin system activation. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s13578-026-01633-9.
SN - 2045-3701
ER -